Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Trial Profile

Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PharmaMar
  • Most Recent Events

    • 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
    • 13 Jun 2011 Actual end date changed from 24 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Status changed from recruiting to completed as stated in a PharmaMar media release dated 24 November 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top